Oracle to acquire Relsys

The purchase of Relsys, which develops operations management applications for drug, biotech, and medical-device companies, is designed to bolster company's health sciences unit.

Oracle on Monday announced plans to acquire Relsys, which develops drug safety and risk management applications.

The acquisition, which is expected to close by June, is designed to bolster Oracle's Health Sciences Global Business Unit, formed last summer. Health sciences is one of a number of industry sectors into which Oracle is delving via a buying spree.

Relsys develops applications designed to aid drug, biotech, and medical-device companies in streamlining their operations, adhering to regulatory compliance and improving the safety of their products.

With the acquisition, Oracle aims to provide its customers with the ability to identify safety risks earlier in the development cycle, as well as improvements in tracking the performance of their products after they hit the market.

Financial terms of the deal were not disclosed.

About the author

    Dawn Kawamoto covered enterprise security and financial news relating to technology for CNET News.

     

    Join the discussion

    Conversation powered by Livefyre

    Show Comments Hide Comments
    Latest Galleries from CNET
    15 crazy old phones from a Korean museum (pictures)
    10 gloriously geeky highlights from 2014 (pictures)
    2015.5 Volvo XC60: updated tech, understated design
    Busted! CNET readers show us their broken devices (pictures)
    Take a closer look at the BlackBerry Classic (pictures)